³»¼Àç

[179]±Ç


	ë³´ë“œì¹´, ì²´í™‰ ê·¸ë¦¬ê³ ë°±ì¡°ì˜ í˜¸ìˆ˜
	ÀúÀÚ \| ë°•ëª…ìš©ã†ë°• ë²” ì´ê³ ë¦¬
	ÃâÆÇ»ç \| ì´ì¹´ë£¨ìŠ¤ë¯¸ë””ì–´

	ì Šì€ ë¶€ìž, ë°°ì¢…ì°¬ì˜ 100ì–µ ë§Œë“¤ê¸°
	ÀúÀÚ \| ë°°ì¢…ì°¬
	ÃâÆÇ»ç \| ì—ì´ì§€21

	íƒë¼ë¬¸ê²¬ë¡, ë°”ë‹¤ë°–ì˜ ë„“ì€ ì„¸ìƒ
	ÀúÀÚ \| ì •ìš´ê²½(ì—ìž: ì •ë¯¼)
	ÃâÆÇ»ç \| íœ´ë¨¸ë‹ˆìŠ¤íŠ¸

	BE 2.0 (Beyond Entre
	ÀúÀÚ \| Jim Collins ì™¸
	ÃâÆÇ»ç \| Portfolio

	The Biogenerics Mark
	Everyone is familiar with generic drugs that were once proprietary. As soon as the patent runs out, companies rush in with their version of a popular drug.


	ë³´ë“œì¹´, ì²´í™‰ ê·¸ë¦¬ê³ ë°±ì¡°ì˜ í˜¸ìˆ˜
	ÀúÀÚ \| ë°•ëª…ìš©ã†ë°• ë²” ì´ê³ ë¦¬
	ÃâÆÇ»ç \| ì´ì¹´ë£¨ìŠ¤ë¯¸ë””ì–´

	ì Šì€ ë¶€ìž, ë°°ì¢…ì°¬ì˜ 100ì–µ ë§Œë“¤ê¸°
	ÀúÀÚ \| ë°°ì¢…ì°¬
	ÃâÆÇ»ç \| ì—ì´ì§€21

	íƒë¼ë¬¸ê²¬ë¡, ë°”ë‹¤ë°–ì˜ ë„“ì€ ì„¸ìƒ
	ÀúÀÚ \| ì •ìš´ê²½(ì—ìž: ì •ë¯¼)
	ÃâÆÇ»ç \| íœ´ë¨¸ë‹ˆìŠ¤íŠ¸

	BE 2.0 (Beyond Entre
	ÀúÀÚ \| Jim Collins ì™¸
	ÃâÆÇ»ç \| Portfolio

	The Biogenerics Mark
	Everyone is familiar with generic drugs that were once proprietary. As soon as the patent runs out, companies rush in with their version of a popular drug.

³»¼­Àç